# Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections

> **NCT04356144** · — · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 58 (actual)

## Conditions studied

- Disseminated Intravascular Coagulation
- Critical Illness
- Sars-CoV2
- Viral Infection
- Coagulation Disorder, Blood
- Covid19

## Interventions

- **DIAGNOSTIC_TEST:** Thrombin Generation Assay (TGA)
- **DIAGNOSTIC_TEST:** Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)

## Key facts

- **NCT ID:** NCT04356144
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-15
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-02-01
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2021-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04356144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04356144, "Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04356144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*